<div id="readability-page-1"><ul><li>Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals</li></ul><p>Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) - Research analysts at  Cantor Fitzgerald cut their FY2025 earnings per share (EPS) estimates for shares of Xenon Pharmaceuticals  in a report released on  Tuesday, August 12th. Cantor Fitzgerald analyst J. Schimmer now forecasts that the biopharmaceutical company will earn ($3.85) per share for the year, down from their previous estimate of ($3.43). The consensus estimate for Xenon Pharmaceuticals' current full-year earnings is ($3.10) per share. Cantor Fitzgerald also issued estimates for Xenon Pharmaceuticals' FY2026 earnings at ($4.08) EPS.</p><p>Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last issued its earnings results on Monday, August 11th. The biopharmaceutical company reported ($1.07) earnings per share for the quarter, missing the consensus estimate of ($1.03) by ($0.04). During the same quarter in the prior year, the firm posted ($0.75) earnings per share. </p><div><p><span></span><span>Get <strong>Xenon Pharmaceuticals</strong> alerts:</span></p></div><p>Several other research firms have also recently weighed in on XENE. Needham &amp; Company LLC dropped their price objective on Xenon Pharmaceuticals from $60.00 to $55.00 and set a &#34;buy&#34; rating for the company in a report on Tuesday, May 13th. William Blair  reiterated an &#34;outperform&#34; rating on shares of Xenon Pharmaceuticals in a report on Monday, May 5th. Wells Fargo &amp; Company dropped their price objective on Xenon Pharmaceuticals from $50.00 to $47.00 and set an &#34;overweight&#34; rating for the company in a report on Tuesday, May 13th. Royal Bank Of Canada lowered their target price on Xenon Pharmaceuticals from $57.00 to $55.00 and set an &#34;outperform&#34; rating for the company in a research note on Tuesday. Finally, Wall Street Zen cut Xenon Pharmaceuticals from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research note on Wednesday, May 21st. One research analyst  has rated the stock with a sell rating and eleven have given a buy rating to the stock. Based on data from MarketBeat, Xenon Pharmaceuticals currently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $53.20.</p><p><b>Get Our Latest Report on Xenon Pharmaceuticals</b></p><h2>Xenon Pharmaceuticals Stock Performance</h2><p>NASDAQ XENE opened at $37.67 on Thursday. Xenon Pharmaceuticals has a fifty-two week low of $26.74 and a fifty-two week high of $46.00. The stock has a 50 day simple moving average of $32.31 and a two-hundred day simple moving average of $34.09. The stock has a market cap of $2.90 billion, a P/E ratio of -10.61 and a beta of 1.16. </p><h2>Institutional Inflows and Outflows</h2><p>A number of institutional investors and hedge funds have recently added to or reduced their stakes in XENE. Geode Capital Management LLC increased its position in  Xenon Pharmaceuticals by 1.0% during the 4th quarter. Geode Capital Management LLC now owns 69,529 shares of the biopharmaceutical company's stock valued at $2,726,000 after buying an additional 720 shares in the last quarter.  Raymond James Financial Inc. bought a new position in  Xenon Pharmaceuticals during the 4th quarter valued at approximately $797,000.  Barclays PLC increased its position in  Xenon Pharmaceuticals by 20.9% during the 4th quarter. Barclays PLC now owns 18,127 shares of the biopharmaceutical company's stock valued at $711,000 after buying an additional 3,134 shares in the last quarter.  XTX Topco Ltd bought a new position in  Xenon Pharmaceuticals during the 4th quarter valued at approximately $316,000.  Finally, Walleye Capital LLC increased its position in  Xenon Pharmaceuticals by 111.5% during the 4th quarter. Walleye Capital LLC now owns 221,982 shares of the biopharmaceutical company's stock valued at $8,702,000 after buying an additional 117,022 shares in the last quarter. Institutional investors own  95.45% of the company's stock. </p><h2>Xenon Pharmaceuticals Company Profile</h2> (Get Free Report)<p>Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.</p><h2>Read More</h2><ul><li>Five stocks we like better than Xenon Pharmaceuticals</li><li>REIT Stocks - Best REIT Stocks to Add to Your Portfolio Today</li><li>Data Centers Create a Bull Case for These Nuclear 3 Stocks</li><li>What is the Nikkei 225 index?    </li><li>Tesla’s Pennant Just Snapped: Here’s What It Means for the Stock</li><li>5 Top Rated Dividend Stocks to Consider</li><li>3 Companies That Will Profit From Trump's Semiconductor Tariffs</li></ul> <p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9WEVORQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9WEVORQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Xenon Pharmaceuticals Right Now?</h2><p>Before you consider Xenon Pharmaceuticals, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xenon Pharmaceuticals wasn't on the list.</p><p>While Xenon Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

XENE

<p>Cantor Fitzgerald has reduced its FY2025 EPS estimate for Xenon Pharmaceuticals (NASDAQ:XENE) from ($3.43) to ($3.85), while the consensus estimate stands at ($3.10). The firm also projected FY2026 EPS at ($4.08). Xenon reported a quarterly EPS of ($1.07), missing estimates. Several analysts have adjusted their price targets, with an average rating of "Moderate Buy" and a consensus target price of $53.20. The stock opened at $37.67, with a market cap of $2.90 billion and institutional ownership at 95.45%.</p>

XENE FY2025 EPS Estimate Decreased by Cantor Fitzgerald